[1]叶旸真,李泓涛,李晶,等.基于独立干预RCT分析浮针疗法优势病种[J].西部中医药,2026,39(08):44-49.[doi:10.12174/j.issn.2096-9600.2026.08.11]
　YE Yangzhen,LI Hongtao,LI Jing,et al.Analysis of the Dominant Diseases Treated with Fu?s Subcutaneous Needling Based on Independent Intervention Randomized Controlled Trials[J].Western Journal of Traditional Chinese Medicine,2026,39(08):44-49.[doi:10.12174/j.issn.2096-9600.2026.08.11]
点击复制

基于独立干预RCT分析浮针疗法优势病种()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年08期
页码:
44-49
栏目:
二次研究
出版日期:
2026-07-29

文章信息/Info

Title:
Analysis of the Dominant Diseases Treated with Fu?s Subcutaneous Needling Based on Independent Intervention Randomized Controlled Trials
作者:
叶旸真1,2,3, 李泓涛2,3, 李晶2, 杜元灏2
1.青浦区中医医院，上海 201799
2.天津中医药大学第一附属医院针灸科/国家中医针灸临床 医学研究中心，天津 300381
3.天津中医药大学，天津 301617
Author(s):
YE Yangzhen1,2,3, LI Hongtao2,3, LI Jing2, DU Yuanhao2
1.Qingpu District Hospital of TCM, Shanghai 201799, China
2.Acupuncture Department, First Teaching Hospital of Tianjin University of TCM/National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
3.Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
关键词:
浮针; 优势病种; 独立干预; 随机对照试验; 文献研究
Keywords:
’s subcutaneous needling; dominant diseases; independent intervention; randomized controlled trials; literature review
分类号:
R245.31
DOI:
10.12174/j.issn.2096-9600.2026.08.11
文献标志码:
A
摘要:
目的探究浮针优势病种及应用现状，以更好指导临床和推广使用。 方法检索中国知网（CNKI）、万方（WF）、维普（VIP）数据库，筛选全部含有“浮针”的文献，运用文献计量学方法统计年度发表数量、病种分类，筛选浮针独立干预的随机对照试验（randomized controlled trial，RCT）文献≥5篇确定为优势病种，并对浮针独立干预且RCT≥10篇的病种采用改良的Jadad量表和Cochrane偏倚风险评估工具进行质量评价。 结果共筛选出临床文献899篇，浮针独立干预RCT文章135篇，最终纳入浮针独立干预且RCT≥10篇的3个病种共计41篇RCT进行循证评价。浮针适应症覆盖7个疾病系统，达57种，优势病种9个，集中在肌肉骨骼和结缔组织系统的颈椎病、肩周炎、腰椎间盘突出症、膝骨性关节炎、肱骨外上髁炎、肌筋膜炎，神经系统的中风病，以及其他类别中的医源性术后疼痛、带状疱疹后遗神经痛。 结论现阶段浮针适应症较为广泛，优势病种较为集中，以颈椎病、腰椎间盘突出症、膝骨性关节炎为代表，通过文献循证评价发现，相关研究普遍存在文献质量偏低、风险偏倚不确定的现象，建议今后提高试验设计的规范性和严谨性。
Abstract:
ObjectiveTo explore the dominant diseases and current application status of Fu’s subcutaneous needling, in order to better guide clinical practice and promote its widespread use. MethodsThe China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were searched to retrieve all literature containing the term "Fu’s subcutaneous needling." Bibliometric methods were used to analyze the annual number of publications and disease classification. Randomized controlled trial (RCT) literature involving Fu’s subcutaneous needling as an independent intervention was screened, and diseases with five or more RCTs were identified as dominant diseases. For those diseases with ten or more RCTs of independent Fu’s subcutaneous needling intervention, quality assessment was conducted using the modified Jadad Scale and the Cochrane Risk of Bias Tool. ResultsA total of 899 clinical articles were screened, among which 135 were randomized controlled trials (RCTs) involving Fu’s subcutaneous needling as an independent intervention. Ultimately, 41 RCTs covering three diseases, each with 10 or more RCTs of independent Fu’s subcutaneous needling intervention, were included for evidence-based evaluation. Fu’s subcutaneous needling is indicated for 57 diseases across 7 disease systems, with 9 dominant diseases. These are primarily concentrated in the musculoskeletal and connective tissue system, including cervical spondylosis, frozen shoulder (adhesive capsulitis), lumbar disc herniation, knee osteoarthritis, lateral epicondylitis of the humerus (tennis elbow), and myofasciitis; in the nervous system, including stroke; and in other categories, including iatrogenic postoperative pain and postherpetic neuralgia. ConclusionAt present, Fu’s subcutaneous needling has a relatively wide range of indications, with its dominant diseases being relatively concentrated, particularly represented by cervical spondylosis, lumbar disc herniation, and knee osteoarthritis. Evidence-based evaluation of the literature reveals that related studies generally suffer from low literature quality and unclear risk of bias. It is recommended that future research improve the standardization and rigor of trial design.

相似文献/References:

[1]杨江霞,符仲华.浅析浮针的理论与临床研究[J].西部中医药,2015,28(06):156.[doi:2015/6/16 0:00:00]
[2]萧钦,张小娟△,李振宇,等.浮针联合脊痹丸治疗腰椎间盘突出症47例[J].西部中医药,2017,30(04):108.
　XIAO Qin,ZHANG Xiaojuan,LI Zhenyu,et al.Floating Needle Combined with JiBi Pill in the Treatment for 47 Cases with Lumbar Disc Herniation[J].Western Journal of Traditional Chinese Medicine,2017,30(08):108.
[3]梁安琦,韩雅欣,刘步平.浮针配合肾关穴治疗急性肩周炎临床观察[J].西部中医药,2020,33(07):135.[doi:10.12174/j.issn.1004-6852.2020.07.36]
　LIANG Anqi,HAN Yaxin,LIU Buping.Clinical Observation on Floating Needle and Shenguan Points in Treating Acute Scapulohumeral Periarthritis[J].Western Journal of Traditional Chinese Medicine,2020,33(08):135.[doi:10.12174/j.issn.1004-6852.2020.07.36]
[4]赵秀秀,李博,孙健.浮针文献计量研究与可视化分析[J].西部中医药,2024,37(07):63.[doi:10.12174/j.issn.2096-9600.2024.07.15]
　ZHAO Xiuxiu,LI Bo,SUN Jian.Visualization Analysis and Bibliometric Study of the Floating Needles[J].Western Journal of Traditional Chinese Medicine,2024,37(08):63.[doi:10.12174/j.issn.2096-9600.2024.07.15]

备注/Memo

备注/Memo:
天津市自然科学基金（18JCYBJC94200）。叶旸真（1996—），男，硕士学位，医师。研究方向：针灸病谱及针灸治疗脑血管病研究。
更新日期/Last Update: 2026-08-15